Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781937 | 0.85 | DDB1 (0.32) | CYP3A4DDB1CRBN | |
| SCHEMBL3787568 | 0.78 | MAOA (0.32) | DDB1CRBN | |
| SCHEMBL3790442 | 0.78 | CYP3A4 (0.35) | CYP3A4DDB1CRBNKDM1A | |
| SCHEMBL3781521 | 0.77 | DDB1 (0.33) | CYP3A4DDB1CRBN | |
| SCHEMBL3782077 | 0.76 | TP53 (0.36) | TP53CYP3A4DDB1CRBN | |
| SCHEMBL3808736 | 0.76 | DDB1 (0.33) | CYP3A4DDB1CRBN | |
| SCHEMBL3788291 | 0.74 | DDB1 (0.33) | CYP3A4DDB1CRBN | |
| SCHEMBL3787414 | 0.74 | CYP3A4 (0.34) | CYP3A4DDB1CRBN | |
| SCHEMBL3784578 | 0.73 | CYP3A4 (0.35) | CYP3A4DDB1CRBN | |
| SCHEMBL3786700 | 0.73 | DDB1 (0.32) | CYP3A4DDB1CRBNKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | TP53 2819/4885CYP3A4 177/4885DDB1 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.